# US 2017/0281752 A1 · Antigen Delivery System > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2017/0281752 A1 - Document ID: US20170281752A1 - Status: Published application - Kind: A1 - Application number: 15/626,075 - Filed: 2017-06-17 - Published: 2017-10-05 - Earliest claimed: 2014-12-17 - Assignees: SRI International - Applicants: Sri International - Inventors: Kathlynn C. Brown; Benjamin J. Umlauf - Web page: https://patentgrep.com/patent/US20170281752A1 ## CPC - A61K 39/285: Vaccinia virus or variola virus - A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) - A61K 39/165: Mumps or measles virus - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers} - A61K 2039/585: {wherein the target is cancer} - A61K 2039/605: {MHC molecules or ligands thereof} - C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell. ## Claims ### Claim 1 A minimal antigen delivery system consisting essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class I restricted peptide and surface-modified with a cancer-specific cell targeting peptide which mediates binding and internalization of the liposomes into a target cell. ### Claim 2 (depends on 1) The system of claim 1, wherein the antigen is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide. ### Claim 3 (depends on 1) The system of claim 1, wherein the antigen is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide, that is measles virus hemagglutinin peptide H250. ### Claim 4 (depends on 1) The system of claim 1, wherein the antigen is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide, that is smallpox virus H-2Kd-restricted vaccinia-specific peptide, A5275-83 (VACV-A52). ### Claim 5 (depends on 1) The system of claim 1, wherein the cell-targeting peptide is H1299.3. ### Claim 6 (depends on 2) The system of claim 2, wherein the cell-targeting peptide is H1299.3. ### Claim 7 (depends on 3) The system of claim 3, wherein the cell-targeting peptide is H1299.3. ### Claim 8 (depends on 4) The system of claim 4, wherein the cell-targeting peptide is H1299.3. ### Claim 9 (depends on 1) The system of claim 1 that does not comprise any viral particles, toxins, or biologically-derived material. ### Claim 10 (depends on 1) A method of making an antigen delivery system of claim 1, comprising the step(s) of: surface modifying the PEGylated stealth liposomes loaded with the HLA class I restricted peptide by conjugating to the surface the cell targeting peptide. ### Claim 11 (depends on 1) A method of making an antigen delivery system of claim 1, comprising the step(s) of: loading the PEGylated stealth liposomes by forming the liposomes in the presence of the class restricted peptide; and surface modifying the PEGylated stealth liposomes loaded with the HLA class I restricted peptide by conjugating to the surface the cell targeting peptide. ### Claim 12 (depends on 1) A method of using the antigen delivery system of claim 1, comprising the step(s) of: introducing the antigen delivery system into a host in need thereof. ### Claim 13 (depends on 1) A method of using the antigen delivery system of claim 1, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 14 (depends on 2) A method of using the antigen delivery system of claim 2, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 15 (depends on 3) A method of using the antigen delivery system of claim 3, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 16 (depends on 4) A method of using the antigen delivery system of claim 4, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 17 (depends on 5) A method of using the antigen delivery system of claim 5, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 18 (depends on 6) A method of using the antigen delivery system of claim 6, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 19 (depends on 7) A method of using the antigen delivery system of claim 7, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell. ### Claim 20 (depends on 8) A method of using the antigen delivery system of claim 8, comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.